Who are Medium-dose anrikefon's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Propafenone i.v., Flecainide controlled release, USL255, TD-4208, TAK-816, TV-46000.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/medium-dose-anrikefon.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Medium-dose anrikefon — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Medium-dose anrikefon (Medium-dose anrikefon) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sodium channel blocker. Area: Cardiovascular.

marketed Sodium channel blocker Nav1.5 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Medium-dose anrikefon (Medium-dose anrikefon) — Peking University First Hospital. Anrikefon is a selective inhibitor of the sodium channel Nav1.5, which helps to regulate the heart's rhythm.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Medium-dose anrikefon TARGET	Medium-dose anrikefon	Peking University First Hospital	marketed	Sodium channel blocker	Nav1.5
Propafenone i.v.	Propafenone i.v.	Charles University, Czech Republic	marketed	Class IC antiarrhythmic agent	Cardiac sodium channel (Nav1.5)
Flecainide controlled release	Flecainide controlled release	MEDA Pharma GmbH & Co. KG	marketed	Class IC antiarrhythmic agent	Cardiac voltage-gated sodium channel (Nav1.5)
USL255	USL255	Upsher-Smith Laboratories	phase 3	sodium-activated potassium channel inhibitor	Nav1.5
TD-4208	TD-4208	Mylan Inc.	phase 3	Sodium-activated potassium channel inhibitor	Nav1.5
TAK-816	TAK-816	Takeda	phase 3	Sodium-activated potassium channel inhibitor	Nav1.5
TV-46000	TV-46000	Teva Branded Pharmaceutical Products R&D, Inc.	phase 3	Sodium-activated potassium channel inhibitor	Nav1.5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sodium channel blocker class)

Peking University First Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Medium-dose anrikefon — Competitive Intelligence Brief. https://druglandscape.com/ci/medium-dose-anrikefon. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing